Edwards Lifesciences Corp (EW) shows an admirable performance despite recent market fluctuations. Dominated by
institutional shareholders who possess a significant percentage of the company, it has a consensus rating of '
Moderate Buy'. EW's position was strengthened by TD Asset Management and others buying stakes in the company. The stock has been trading higher on Wall Street, and despite a 9.7% dip over a week, the yearly returns are more in line with earnings growth.
Up by 21.8% YTD, EW is reportedly on an upward surge, with various factors contributing to growth. Commerce Bank and Wells Fargo & Company MN have also increased their stakes in the company. Despite underperforming the market, EW's earnings are expected to grow and have shown a robust Q4. Even though the company witnessed a fall in Q4 despite double-digit revenue growth, strong institutional backing and solid earnings estimates hint at promising underlying business. In an opportune move, the corporation plans to spin-off its critical care unit in 2024. Edmond DE Rothschild Holding S.A. retains a substantial stake in EW. Bouncing from some losses, EW's
stock seems poised to rally at an accelerating pace from Q1 earnings that top impressions.
Edwards Lifesciences Corp EW News Analytics from Tue, 29 Aug 2023 07:00:00 GMT to Thu, 30 May 2024 16:02:13 GMT -
Rating 7
- Innovation 4
- Rumor -3
